FDA accuses CytoDyn of cherry-picking COVID data To view this email as a web page,
click here Medicago, GSK post positive midphase data on plant-derived COVID-19 vaccine COVID-19 tracker: India's vaccine export ban likely to last until October; U.S. vaccinated 600,000 kids last week CytoDyn shares plummet after FDA blasts the biotech for cherry-picking COVID-19 data Advocate Aurora Health reports $352M gain for Q1 2021 even without COVID relief funds CommonSpirit Health accelerates COVID-19 rebound with $539M in operating gains UPDATED Coronavirus tracker: CDC officials who raised early COVID-19 warnings depart agency Featured Story | By Nick Paul Taylor Medicago and GlaxoSmithKline have presented interim phase 2 data on their adjuvanted COVID-19 vaccine candidate. The results suggest the plant-derived jab CoVLP+AS03 is somewhat differentiated from other vaccines through the mixed cellular response it triggers. read more |
| |
|---|
|
Top Stories By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner India likely won't resume major exports of COVID-19 vaccines until October, government sources tell Reuters, a major hit to the world's poorest nations. The U.S. vaccinated roughly 600,000 adolescents with the Pfizer-BioNTech vaccine last week, the CDC director reports. And more headlines. read more By Annalee Armstrong In an unprecedented public rebuke, the FDA accused CytoDyn of trying to cherry-pick data from two failed studies of leronlimab in COVID-19 patients to claim the drug is effective. Plus, a stockholder has filed a class action lawsuit alleging that CytoDyn made false and misleading statements about the viability of leronlimab in treating COVID-19, a securities filing shows. read more By Dave Muoio The Illinois- and Wisconsin-based nonprofit had lost more than $1.3 billion during the same time last year. The system wrote that much of the swing was driven by the performance of its various investments. read more By Dave Muoio CommonSpirit reversed last year's losses in spite of persistent low volumes and higher costs. The Catholic health system said it's still planning for "a low, but steady" stream of COVID-19 patients across its inpatient locations during the foreseeable future. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more |
|
